You need to be logged in to view this video
A Biotech Company Developing a Major Medical Breakthrough: Learn About Opportunities for Pre-IPO Investments for Qualified Investors
Released on Tuesday, September 15, 2020•BIOTECH
Zhittya Genesis Medicine is a biotech company advancing, through FDA-authorized clinical trials, a biological drug that triggers angiogenesis (growth of new blood vessels) in damaged or ischemic tissues. This breakthrough medical treatment has the potential to reverse diseases which cause suffering and death for over 50% of all adults worldwide, including heart disease, strokes, diabetic foot ulcers, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Zhittya believes its drug could extend human life an additional 20 to 30 years with good quality health.
Dr. Jack Jacobs has been involved in the healthcare industry for over 25 years and has extensive expertise in supervising drug manufacturing operations and the design and implementation of preclinical animal trials and US FDA-authorized clinical trials. He started a new department of biological chemistry at Merck and for 15 years worked with Mr. Montano as cardiovascular biotherapeutics' chief scientific officer where Dr. Jacobs oversaw FDA-authorized clinical trials in which FGF-1 was tested in a number of medical indications, including coronary artery disease, diabetic foot ulcers, and peripheral artery disease. He also oversaw the manufacturing of clinical lots of FGF-1 that were used in those clinical studies. Dr. Jacobs received a BS degree from Davidson College and a PhD in molecular biology from Washington University, St. Louis.
Filter By Category
Filter By Keywords